Headlines about Endologix (NASDAQ:ELGX) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endologix earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.963645759542 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several brokerages have recently weighed in on ELGX. Canaccord Genuity reissued a “hold” rating and set a $5.00 target price on shares of Endologix in a research report on Wednesday, September 27th. JPMorgan Chase & Co. lowered Endologix from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Stifel Nicolaus cut their price target on Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a research report on Wednesday, November 8th. Finally, BidaskClub lowered Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. Endologix currently has a consensus rating of “Hold” and a consensus price target of $5.41.
Endologix (ELGX) opened at $4.59 on Friday. Endologix has a 12 month low of $4.08 and a 12 month high of $7.66. The firm has a market capitalization of $381.38, a P/E ratio of -4.94 and a beta of 0.72. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Endologix (ELGX) Stock Price” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-endologix-elgx-stock-price.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.